NCT04592523Completed
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 271 (actual)
- First submitted
- 14 Oct 2020
- Start date
- 5 Sept 2019
- Primary completion date
- 12 Mar 2026
- Lead sponsor
- Takeda
- Diseases
- Lung cancer
- NCT number
- NCT04592523
What you commit to
- Study type: Observational
- Participants enrolled: 271
- From 5 Sept 2019 to the primary completion date, 12 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with brigatinib outside of the locally approved label in Korea.
Other
- Whom brigatinib is contraindicated as per product label.
- Participating in other clinical trials of NSCLC treatment.
Who the study is looking for
- With ALK-positive advanced or metastatic NSCLC.
- Who initiate brigatinib for the first time.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pusan National University Hospital Coordinator of this site? Confirm its status | Busan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.